Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SDRT with or without Adjuvant Systemic Therapy in Oligometastatic Prostate Cancer
NCT04031378Phase 2Unknown
- Sponsor
- Champalimaud Foundation
- Start
- Sep 2019
- Primary completion
- Nov 2019
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in Metastatic Prostate Cancer (mPC) and prostate adenocarcinoma, sponsored by Champalimaud Foundation. Primary endpoint: Number of participants with post-treatment abnormal laboratory values (PSA relapse) at 5 years. Status: unknown.
02
Conditions
Metastatic Prostate Cancer (mPC)prostate adenocarcinoma
Beyond the preview
Go deeper on NCT04031378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04031378.